Holen Sie sich die Stockscreener-App
2.80
2.56%
0.07
Schlusskurs vom Vortag:
$2.73
Offen:
$2.74
24-Stunden-Volumen:
1.46M
Relative Volume:
0.59
Marktkapitalisierung:
$251.78M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.9722
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-7.59%
1M Leistung:
-16.67%
6M Leistung:
+45.83%
1J Leistung:
-26.12%
1-Tages-Spanne:
$2.7324
$2.921
1-Wochen-Bereich:
$2.60
$3.08
52-Wochen-Spanne:
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.80 | 245.48M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat
Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN
What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser
Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser
HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest
Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest
Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr
Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks
What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com
Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com
H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada
Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest
Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr
Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com
Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr
Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks
Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛
Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest
Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria
Editas: Q2 Earnings Snapshot - Greenwich Time
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN
What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada
Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Editas Medicine Inc-Aktie (EDIT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jul 31 '25 |
Sale |
2.49 |
5,121 |
12,757 |
64,398 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):